Yun-Chung Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yun-Chung Liu has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Luan-Yin Chang
Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
11 shared publications - Feipei Lai
Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan
6 shared publications Li-Min Huang
Division of Pediatric Infectious Diseases, Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
6 shared publicationsJong-Min Chen
Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
5 shared publications- Tu-Hsuan Chang
Department of Pediatrics, Chi Mei Medical Center, Tainan, Taiwan
5 shared publications Ping-Ing Lee
Department of Pediatrics, National Taiwan University Children's Hospital, Taipei, Taiwan; Department of Pediatrics, National Taiwan University College of Medicine, National Taiwan University, Taipei, Taiwan
4 shared publications
Latest Publications
- 8 July 2026
- Published by Springer Nature in Journal of Healthcare Informatics Research
- Vol. 10 (3) , 654-665
Leveraging LLMs for Title and Abstract Screening for Systematic Review: A Cost-effective Dynamic Few-shot Learning Approach
- 8 July 2026
- Published by Springer Nature in Journal of Healthcare Informatics Research
- Vol. 10 (3) , 654-665
Leveraging LLMs for Title and Abstract Screening for Systematic Review: A Cost-effective Dynamic Few-shot Learning Approach
- 20 April 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (4) , e70929
Emergence of Echovirus 11 in Severe and Neonatal Enterovirus Infections: A 9‐Year Retrospective Study in Taiwan Before and After the COVID‐19 Pandemic
Enteroviruses (EVs) cause a wide range of pediatric illnesses. In Taiwan, changes in serotype distribution and COVID‐19‐related public health measures may have influenced recent EV trends. We retrospectively reviewed EV‐positive pediatric inpatients (< 18 years) at National Taiwan University Hospital from 2015 to 2023. Cases were identified via PCR or viral culture. Among 678 cases, incidence declined markedly during the COVID‐19 period but rebounded after public health restrictions were relaxed, with seasonal peaks in June persisting. Echovirus 11 emerged as the predominant serotype among neonatal cases (23.1%) and severe cases (9.5%), whereas EV‐A71 was mainly associated with hand‐foot‐mouth disease. Severe cases were significantly younger (median 0.8 vs. 1.5 years, p = 0.002) and more likely to have underlying conditions, including congenital syndromes and cardiovascular diseases. The only mortality occurred in a neonate with echovirus 11 infection. Viral or bacterial co‐detections were not associated with severity. Echovirus 11 has replaced EV‐A71 as a leading cause of severe and neonatal EV infections in Taiwan. Younger age and underlying conditions were significant risk factors for severe disease. Ongoing surveillance and vaccine development should prioritize currently circulating virulent serotypes and high‐risk pediatric populations.
- 20 April 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (4) , e70929
Emergence of Echovirus 11 in Severe and Neonatal Enterovirus Infections: A 9‐Year Retrospective Study in Taiwan Before and After the COVID‐19 Pandemic
Enteroviruses (EVs) cause a wide range of pediatric illnesses. In Taiwan, changes in serotype distribution and COVID‐19‐related public health measures may have influenced recent EV trends. We retrospectively reviewed EV‐positive pediatric inpatients (< 18 years) at National Taiwan University Hospital from 2015 to 2023. Cases were identified via PCR or viral culture. Among 678 cases, incidence declined markedly during the COVID‐19 period but rebounded after public health restrictions were relaxed, with seasonal peaks in June persisting. Echovirus 11 emerged as the predominant serotype among neonatal cases (23.1%) and severe cases (9.5%), whereas EV‐A71 was mainly associated with hand‐foot‐mouth disease. Severe cases were significantly younger (median 0.8 vs. 1.5 years, p = 0.002) and more likely to have underlying conditions, including congenital syndromes and cardiovascular diseases. The only mortality occurred in a neonate with echovirus 11 infection. Viral or bacterial co‐detections were not associated with severity. Echovirus 11 has replaced EV‐A71 as a leading cause of severe and neonatal EV infections in Taiwan. Younger age and underlying conditions were significant risk factors for severe disease. Ongoing surveillance and vaccine development should prioritize currently circulating virulent serotypes and high‐risk pediatric populations.
- Top Cited PapersOpen Access
- 3 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Representation learning to advance multi-institutional studies with electronic health record data from US and France
The widespread adoption of electronic health records has created new opportunities for translational clinical research, yet this promise remains constrained by fragmented data across privacy-siloed institutions and substantial heterogeneity in local coding practices. While privacy-preserving collaborative learning allows institutions to work together without sharing patient-level data, it does not address inconsistencies in how clinical concepts are represented across sites. We introduce a graph-based framework that addresses this gap by treating data harmonization as a scalable representation learning problem. Rather than relying on fixed standards or manual mappings, the framework integrates institution-specific summary statistics from health records, curated biomedical knowledge graphs, and semantic information derived from large language models to learn a shared semantic space. This joint learning approach aligns diverse, site-specific vocabularies while preserving patient privacy. Evaluated across seven institutions and two languages, the framework provides a robust, data-centric foundation for training and deploying clinical models across heterogeneous healthcare systems.
- 3 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessRepresentation learning to advance multi-institutional studies with electronic health record data from US and France
The widespread adoption of electronic health records has created new opportunities for translational clinical research, yet this promise remains constrained by fragmented data across privacy-siloed institutions and substantial heterogeneity in local coding practices. While privacy-preserving collaborative learning allows institutions to work together without sharing patient-level data, it does not address inconsistencies in how clinical concepts are represented across sites. We introduce a graph-based framework that addresses this gap by treating data harmonization as a scalable representation learning problem. Rather than relying on fixed standards or manual mappings, the framework integrates institution-specific summary statistics from health records, curated biomedical knowledge graphs, and semantic information derived from large language models to learn a shared semantic space. This joint learning approach aligns diverse, site-specific vocabularies while preserving patient privacy. Evaluated across seven institutions and two languages, the framework provides a robust, data-centric foundation for training and deploying clinical models across heterogeneous healthcare systems.
- Open Access
- 11 May 2024
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 57 (4) , 546-553
Seroprevalence of SARS-CoV-2 in self-reported COVID-19-free children
- 11 May 2024
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 57 (4) , 546-553
Open AccessSeroprevalence of SARS-CoV-2 in self-reported COVID-19-free children
- Open Access
- 9 May 2024
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 57 (4) , 573-579
Clinical characteristics and risk factors of severe human parainfluenza virus infection in hospitalized children
- 9 May 2024
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 57 (4) , 573-579
Open AccessClinical characteristics and risk factors of severe human parainfluenza virus infection in hospitalized children
- Open Access
- 1 May 2023
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 56 (4) , 772-781
Clinical characteristics of hospitalized children with community-acquired pneumonia and respiratory infections: Using machine learning approaches to support pathogen prediction at admission
- 1 May 2023
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 56 (4) , 772-781
Open AccessClinical characteristics of hospitalized children with community-acquired pneumonia and respiratory infections: Using machine learning approaches to support pathogen prediction at admission
- 15 March 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (3) , e28638
The clinical predictors of and vaccine protection against severe influenza infection in children
Influenza infection in children causes a tremendous global burden. In this study, we aimed to investigate the clinical predictors of severe influenza among children. We retrospectively included hospitalized children who had laboratory‐confirmed influenza infection and were admitted to a medical center in Taiwan between 2010 and 2018. Severe influenza infection was defined as needing intensive care. We compared demographics, comorbidities, vaccine status and outcomes between patients with severe and nonsevere infection. There were 1030 children hospitalized for influenza infection: 162 patients needed intensive care and 868 patients did not. Multivariable analysis revealed that an age below 2 years (adjusted odds ratio [aOR] 3.31, 95% confidence interval [CI] 2.22–4.95), underlying cardiovascular disease (aOR 1.84, 95% CI 1.04–3.25), neuropsychological (aOR 4.09, 95% CI 2.59–6.45) or respiratory disease (aOR 3.87, 95% CI 1.42–10.60), patchy infiltrates (aOR 2.52, 95% CI 1.29–4.93), pleural effusion (aOR 6.56, 95% CI 1.66–25.91), and invasive bacterial coinfection (aOR 21.89, 95% CI 2.19–218.77) were significant clinical predictors of severe disease, whereas severe infection was less likely in individuals who had received influenza and pneumococcal conjugate vaccines (PCVs) (aOR 0.51, 95% CI 0.28–0.91; aOR 0.35, 95% CI 0.23–0.51, respectively). The most significant risk factors associated with severe influenza infection were an age under 2 years, comorbidities (cardiovascular, neuropsychological, and respiratory diseases), patchy infiltrates or effusion shown on chest X‐rays, and bacterial coinfections. The incidence rate of severe disease was significantly lower in those who had received influenza vaccines and PCVs.
- 15 March 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (3) , e28638
The clinical predictors of and vaccine protection against severe influenza infection in children
Influenza infection in children causes a tremendous global burden. In this study, we aimed to investigate the clinical predictors of severe influenza among children. We retrospectively included hospitalized children who had laboratory‐confirmed influenza infection and were admitted to a medical center in Taiwan between 2010 and 2018. Severe influenza infection was defined as needing intensive care. We compared demographics, comorbidities, vaccine status and outcomes between patients with severe and nonsevere infection. There were 1030 children hospitalized for influenza infection: 162 patients needed intensive care and 868 patients did not. Multivariable analysis revealed that an age below 2 years (adjusted odds ratio [aOR] 3.31, 95% confidence interval [CI] 2.22–4.95), underlying cardiovascular disease (aOR 1.84, 95% CI 1.04–3.25), neuropsychological (aOR 4.09, 95% CI 2.59–6.45) or respiratory disease (aOR 3.87, 95% CI 1.42–10.60), patchy infiltrates (aOR 2.52, 95% CI 1.29–4.93), pleural effusion (aOR 6.56, 95% CI 1.66–25.91), and invasive bacterial coinfection (aOR 21.89, 95% CI 2.19–218.77) were significant clinical predictors of severe disease, whereas severe infection was less likely in individuals who had received influenza and pneumococcal conjugate vaccines (PCVs) (aOR 0.51, 95% CI 0.28–0.91; aOR 0.35, 95% CI 0.23–0.51, respectively). The most significant risk factors associated with severe influenza infection were an age under 2 years, comorbidities (cardiovascular, neuropsychological, and respiratory diseases), patchy infiltrates or effusion shown on chest X‐rays, and bacterial coinfections. The incidence rate of severe disease was significantly lower in those who had received influenza vaccines and PCVs.
- Open Access
- 13 January 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 128, 301-306
Differential clinical characteristics and performance of home antigen tests between parents and children after household transmission of SARS-CoV-2 during the Omicron variant pandemic
- 13 January 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 128, 301-306
Open AccessDifferential clinical characteristics and performance of home antigen tests between parents and children after household transmission of SARS-CoV-2 during the Omicron variant pandemic
- Open Access
- 1 June 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (6) , 1073-1080
Clinical characteristics of recurrent pneumonia in children with or without underlying diseases
- 1 June 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (6) , 1073-1080
Open AccessClinical characteristics of recurrent pneumonia in children with or without underlying diseases